Looking at the earnings released by Lilly this morning one just might come away with the impression that Lilly has immunity to the coronavirus and its economic impact. Looking specifically at their diabetes franchise it looks like business as usual. Trulicity, Basaglar and Jardiance all experienced solid growth, while Humalog sales slightly decreased but this had more to do with channel mix/rebates then volume which grew.
To some extent we aren’t overly surprised by these results as we have been noting that coronavirus or not patients still need their meds. The company did note in the earnings press . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.